CAR-T细胞治疗在多发性骨髓瘤中的进展

刘佳慧; 安刚; 王建祥

doi:10.13201/j.issn.1004-2806.2019.07.002

CAR-T细胞治疗在多发性骨髓瘤中的进展

- 中国医学科学院血液病医院血液学研究所(天津, 300020)
基金项目:
国家自然科学基金重点项目（No：81830005）

详细信息

通讯作者: 王建祥,E-mail:wangjx@ihcams.ac.cn

中图分类号: R733.3

收稿日期: 2019-06-06

Progress of CAR-T cell therapy in multiple myeloma

More Information

Corresponding author: WANG Jianxiang, E-mail: wangjx@ihcams.ac.cn

Received Date: 06 June 2019

摘要

- CAR-T /
- 细胞治疗 /
- 多发性骨髓瘤 /
- 进展
- CAR-T /
- cell therapy /
- multiple myeloma /
- progress

HTML全文

参考文献(31)

[1]	Rollig C, Knop S, Bornhauser M.Multiple myeloma[J].Lancet, 2015, 385:2197-2208.
[2]	Palumbo A, Avet-Loiseau H, Oliva S, et al.Revised International Staging System for Multiple Myeloma:A Report From International Myeloma Working Group[J].J Clin Oncol, 2015, 33:2863-2869.
[3]	Garfall AL, Maus MV, Hwang WT, et al.Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma[J].N Engl J Med, 2015, 373:1040-1047.
[4]	Maude SL, Frey N, Shaw PA, et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med, 2014, 371:1507-1517.
[5]	Grupp SA, Kalos M, Barrett D, et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J].N Engl J Med, 2013, 368:1509-1518.
[6]	Porter DL, Levine BL, Kalos M, et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J].N Engl J Med, 2011, 365:725-733.
[7]	Salter AI, Pont MJ, Riddell SR.Chimeric antigen receptor-modified T cells:CD19 and the road beyond[J].2018, 131:2621-2629.
[8]	Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults:a phase 1 dose-escalation trial[J].Lancet, 2015, 385:517-528.
[9]	Brentjens RJ, Davila ML, Riviere I, et al.CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia[J].Sci Transl Med, 2013, 5:177ra138.
[10]	Carpenter RO, Evbuomwan MO, Pittaluga S, et al.B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma[J].Clin Cancer Res, 2013, 19:2048-2060.
[11]	Brudno JN, Maric I, Hartman SD, et al.T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma[J].J Clin Oncol, 2018, 36:2267-2280.
[12]	Ali SA, Shi V, Maric I, et al.T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma[J].Blood, 2016, 128:1688-1700.
[13]	Raje N, Berdeja J, Lin Y, et al.Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma[J].N Engl J Med, 2019, 380:1726-1737.
[14]	Zhao WH, Liu J, Wang BY, et al.A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma[J].J Hematol Oncol, 2018, 11:141.
[15]	Cohen AD, Garfall AL, Stadtmauer EA, et al.B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma[J].J Clin Invest, 2019, 130:2210-2221.
[16]	Palaiologou M, Delladetsima I, Tiniakos D.CD138(syndecan-1) expression in health and disease[J].Histol Histopathol, 2014, 29:177-189.
[17]	Guo B, Chen M, Han Q, et al.CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma[J].J Cellular Immunother, 2016, 2:28-35.
[18]	Ramos CA, Savoldo B, Torrano V, et al.Clinical responses with T lymphocytes targeting malignancy-associated κ light chains[J].J Clin Invest, 2016, 126:2588-2596.
[19]	Danhof S, Gogishvili T, Koch S, et al.CAR-Engineered T Cells Specific for the Elotuzumab Target SLAMF7 Eliminate Primary Myeloma Cells and Confer Selective Fratricide of SLAMF7+ Normal Lymphocyte Subsets[J].Blood, 2015, 126:115.
[20]	Chu J, He S, Deng Y, et al.Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells[J].Clin Cancer Res, 2014, 20:3989-4000.
[21]	Gogishvili T, Danhof S, Prommersberger S, et al.SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes[J].Blood, 2017, 130:2838-2847.
[22]	Wang X, Walter M, Urak R, et al.Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma[J].Clin Cancer Res, 2018, 24:106-119.
[23]	van de Donk N, Richardson PG, Malavasi F.CD38 antibodies in multiple myeloma:back to the future[J].Blood, 2018, 131:13-29.
[24]	Drent E, Groen RW, Noort WA, et al.Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma[J].Haematologica, 2016, 101:616-625.
[25]	Drent E, Themeli M, Poels R, et al.Reducing on-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors By Affinity Optimization[J].Blood, 2016, 128:2170.
[26]	Casucci M, Nicolis di Robilant B, Falcone L, et al.CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma[J].Blood, 2013, 122:3461-3472.
[27]	Lee DW, Gardner R, Porter DL, et al.Current concepts in the diagnosis and management of cytokine release syndrome[J].Blood, 2014, 124:188-195.
[28]	Brudno JN, Kochenderfer JN.Recent advances in CAR T-cell toxicity:Mechanisms, manifestations and management[J].Blood Rev, 2019, 34:45-55.
[29]	James SE, Orgun NN, Tedder TF, et al.Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice[J].Blood, 2009, 114:5454-5463.
[30]	Shah NN, Maatman T, Hari P, et al.Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies[J].Front Oncol, 2019, 9:146.
[31]	Hay AE, Cheung MC.CAR T-cells:costs, comparisons, and commentary[J].J Med Econ, 2019, 12:1-3.